Insulin enhanced thrombin-activatable fibrinolysis inhibitor expression through PI3 kinase/Akt pathway.

被引：0
|
作者：
Hori, Y
Nakatani, K
Yano, Y
Esteban, GC
Morioka, K
Urakawa, H
Maruyama, N
Kitagawa, N
Katsuki, A
Araki, R
Sumida, Y
Adachi, Y
机构：
[1] Mie Univ, Sch Med, Dept Internal Med 3, Tsu, Mie 514, Japan
[2] Mie Univ, Sch Med, Dept Lab Med, Tsu, Mie 514, Japan
来源：
DIABETOLOGIA | 2003年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1222
引用
收藏
页码：A418 / A418
页数：1
相关论文
共 50 条
  • [1] Insulin enhanced thrombin-activable fibrinolysis inhibitor expression through PI3 kinase/Akt pathway
    Hori, Y
    Nakatani, K
    Morioka, K
    Katsuki, A
    Gabazza, EC
    Yano, Y
    Nobori, T
    Adachi, Y
    Sumida, Y
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2005, 15 (02) : 265 - 268
  • [2] PI3-Kinase Inhibitor LY294002 Repressed the Expression of Thrombin-Activatable Fibrinolysis Inhibitor in Human Hepatoma HepG2 Cells
    Masuda, Yutaka
    Yazawa, Jun
    Makino, Yuuka
    Takada, Kimihiko
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2015, 38 (10) : 1529 - 1535
  • [3] Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism
    Erem, Cihangir
    Ucuncu, Ozge
    Yilmaz, Mustafa
    Kocak, Mustafa
    Nuhoglu, Irfan
    Ersoz, Halil Onder
    ENDOCRINE, 2009, 35 (01) : 75 - 80
  • [4] Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism
    Erem, Cihangir
    Ucuncu, Ozge
    Yilmaz, Mustafa
    Kocak, Mustafa
    Nuhoglu, Irfan
    Ersoz, Halil Onder
    ENDOCRINE, 2009, 36 (03) : 473 - 478
  • [5] Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism
    Cihangir Erem
    Ozge Ucuncu
    Mustafa Yilmaz
    Mustafa Kocak
    İrfan Nuhoglu
    Halil Onder Ersoz
    Endocrine, 2009, 35 : 75 - 80
  • [6] Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism
    Cihangir Erem
    Ozge Ucuncu
    Mustafa Yilmaz
    Mustafa Kocak
    İrfan Nuhoglu
    Halil Onder Ersoz
    Endocrine, 2009, 36 : 473 - 478
  • [7] Thrombin-activatable fibrinolysis inhibitor (TAFI) is enhanced in major trauma patients without infectious complications
    Relja, B.
    Lustenberger, T.
    Puttkammer, B.
    Jakob, H.
    Morser, J.
    Gabazza, E. C.
    Takei, Y.
    Marzi, I.
    IMMUNOBIOLOGY, 2013, 218 (04) : 470 - 476
  • [8] Increased Thrombin-Activatable Fibrinolysis Inhibitor and Decreased Tissue Factor Pathway Inhibitor and Thrombomodulin Levels in Children with Hypothyroidism
    Alioglu, Bulent
    Kilic, Nevin
    Simsek, Enver
    Dallar, Yildiz
    JOURNAL OF CLINICAL RESEARCH IN PEDIATRIC ENDOCRINOLOGY, 2012, 4 (03) : 146 - 150
  • [9] Calreticulin regulates insulin receptor expression and its downstream PI3 Kinase/Akt signalling pathway
    Jalali, Shahrzad
    Aghasi, Maliheh
    Yeganeh, Behzad
    Mesaeli, Nasrin
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2008, 1783 (12): : 2344 - 2351
  • [10] Identification of instability elements in the 3′-untranslated region of the human thrombin-activatable fibrinolysis inhibitor mRNA
    Kuo, A
    Boffa, M
    Koschinsky, M
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (05) : E52 - E52
12345